Journal Article Review Ppublish 1 citation
PubMed: 40356246 DOI: 10.1002/ctm2.70320
Mitochondria-derived vesicles: A promising and potential target for tumour therapy.
Clin Transl Med 15(5):e70320
Authors: Xueqiang Peng, Yu Gao, Jiaxing Liu, Xinxin Shi, Wei Li, Yingbo Ma, Xuexin Li, Hangyu Li
Affiliations
- Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, China. Group of Chronic Disease and Environmental Genomics, School of Public Health, China Medical University, Shenyang, China. Shenyang Clinical Medical Research Center for Diagnosis, Treatment and Health Management of Early Digestive Cancer, Shenyang, China.
- Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, China. Shenyang Clinical Medical Research Center for Diagnosis, Treatment and Health Management of Early Digestive Cancer, Shenyang, China.
- Department of General Surgery, The First Hospital of Anhui University of Science & Technology, Huainan, China.
- Depatment of Hepatobiliary Surgery, Air Force Medical Center, Beijing, China.
- Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, China.
- Shenyang Clinical Medical Research Center for Diagnosis, Treatment and Health Management of Early Digestive Cancer, Shenyang, China.
- Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
- Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, China. Shenyang Clinical Medical Research Center for Diagnosis, Treatment and Health Management of Early Digestive Cancer, Shenyang, China. Department of General Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
Abstract
Mitochondria-derived vesicles (MDVs) participate in early cellular defence mechanisms initiated in response to mitochondrial damage. They maintain mitochondrial quality control (MQC) by clearing damaged mitochondrial components, thereby ensuring the normal functioning of cellular processes. This process is crucial for cell survival and health, as mitochondria are the energy factories of cells, and their damage can cause cellular dysfunction and even death. Recent studies have shown that MDVs not only maintain mitochondrial health but also have a significant impact on tumour progression. MDVs selectively encapsulate and transport damaged mitochondrial proteins under oxidative stress and reduce the adverse effects of mitochondrial damage on cells, which may promote the survival and proliferation of tumour cells. Furthermore, it has been indicated that after cells experience mild stress, the number of MDVs significantly increases within 2-6Â h, whereas mitophagy, a process of clearing damaged mitochondria, occurs 12-24Â h later. This suggests that MDVs play a critical role in the early stress response of cells. Moreover, MDVs also have a significant role in intercellular communication, specifically in the tumour microenvironment. They can carry and transmit various bioactive molecules, such as proteins, nucleic acids, and lipids, which regulate tumour cell's growth, invasion, and metastasis. This intercellular communication may facilitate tumour spread and metastasis, making MDVs a potential therapeutic target. Advances in MDV research have identified novel biomarkers, clarified regulatory mechanisms, and provided evidence for clinical use. These breakthroughs pave the way for novel MDV-targeted therapies, offering improved treatment alternatives for cancer patients. Further research can identify MDVs' role in tumour development and elucidate future cancer treatment horizons.
MeSH
Cells, Stress, Physiological, Communication, Neoplasms, Mitochondria, Neoplasm Metastasis, Research, Therapeutics
Cited by
- Mitochondria-derived vesicles: A promising and potential target for tumour therapy. Clin Transl Med, 2025